Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

DoH launches White Paper consultations

The Department of Health has launched a consultation of health bodies on the proposals for patient care and information set out in the White Paper.
The White Paper proposals include plans to allow patients to choose services ‘from any willing provider’. They also suggest patients should be able to choose a provider for diagnosis and chose their health team for treatment, including mental health treatment.
Andrew Lansley said that the NHS will also lead an “information revolution”. Lansley said: “The information revolutions starts from the premise the primary use of information is to support the giving of high quality care.
“The most important source of data is therefore the patient or service users care record with data recorded once a the point of care.”
The Department of Health also published a summery of the responses to the consultation on enabling people to register with a practice of their choice.

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD013309

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel